Daraxonrasib is a selective receptor tyrosine kinase inhibitor targeting c-Met, primarily utilized in the investigation and treatment of non-small cell lung cancer and various solid tumors characterized… Read more
Daraxonrasib is a selective receptor tyrosine kinase inhibitor targeting c-Met, primarily utilized in the investigation and treatment of non-small cell lung cancer and various solid tumors characterized by c-Met overexpression. This category features a comprehensive collection of Daraxonrasib reference standards, including associated metabolites such as N-desmethyl Daraxonrasib and specific degradation products. Pharmaceutical laboratories rely on these high-quality compounds, including stable isotope labelled analogues like Daraxonrasib-13C-d3, to support rigorous impurity profiling and method validation. By utilizing these materials during analytical testing and quality control procedures, researchers can accurately identify, quantify, and monitor trace-level impurities or metabolites within drug formulations. These specialized chemical standards are essential for ensuring the consistency, safety, and regulatory compliance of drug development processes throughout the therapeutic pipeline.